Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 7.7% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a leading insulin delivery and diabetes technology company based in San Diego, California. The company focuses on advanced automated insulin delivery systems like the Tandem Mobi and t:slim X2 insulin pumps.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 7.7% on May 1, 2026 14:16

• Tandem Diabetes Care (TNDM) experienced a strong bullish movement recently.
• Vanguard Capital Management's significant passive institutional investment of over 3.5 million shares in TNDM may have instilled confidence in other investors, contributing to the bullish trend.
• The raised price target by TD Cowen and the positive outlook on TNDM's new products driving future revenue growth likely attracted more investors to the stock.
• The announcement of upcoming conference presentations by Tandem Diabetes Care could have also generated excitement and optimism among investors, further fueling the bullish momentum.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Vanguard Capital Management files 13G for Tandem Diabetes Care (NYSE: TNDM) — 3.55M shares

Vanguard Capital Management has filed a Schedule 13G for Tandem Diabetes Care (NYSE: TNDM), reporting beneficial ownership of 3,553,772 shares, which represents a 5.18% stake in the company. The filing indicates that Vanguard has sole dispositive power over all these shares and sole voting power over 514,853 shares, signaling a significant, passive institutional investment. This disclosure provides transparency regarding Vanguard's substantial holding in Tandem Diabetes Care.

https://www.stocktitan.net/sec-filings/TNDM/schedule-13g-tandem-diabetes-care-inc-passive-investment-disclosure-5-6cb77f818045.html

TD Cowen Raises Tandem Diabetes (TNDM) Price Target, Keeps Buy Rating

TD Cowen has raised its price target for Tandem Diabetes Care (TNDM) from $25 to $28, maintaining a Buy rating. This adjustment follows TNDM's announcement of a pay-as-you-go program and the Mobi Tubeless product, which is expected to drive mid-to-high-teens compound annual revenue growth despite

https://www.insidermonkey.com/blog/td-cowen-raises-tandem-diabetes-tndm-price-target-keeps-buy-rating-1750870/?amp=1

10 Best Medical Stocks to Buy Under $30

This article identifies Tandem Diabetes Care, Inc. (NASDAQ:TNDM) as one of the best medical stocks to buy under $30. TD Cowen recently increased its price target for Tandem Diabetes Care, Inc. to $28 and maintained a Buy rating, citing the company's new pay-as-you-go program and Mobi Tubeless product as drivers for future revenue growth despite short-term distribution model transition headwinds. The firm projects strong gross and EBITDA margins post-transition, highlighting the company's focus on advanced insulin delivery systems.

https://www.insidermonkey.com/blog/10-best-medical-stocks-to-buy-under-30-1750004/2/

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care, Inc. announced that its management will present company updates at two upcoming investor conferences: the BofA Securities 2026 Health Care Conference on May 12, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Webcasts of these presentations will be available live and archived on the company's Investor Center website. Tandem Diabetes Care manufactures and sells advanced automated insulin delivery systems like the Tandem Mobi and t:slim X2 insulin pumps.

https://www.businesswire.com/news/home/20260429093228/en/Tandem-Diabetes-Care-Announces-Upcoming-Conference-Presentations

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care, Inc. announced that its management will present company updates at two upcoming investor conferences: the BofA Securities 2026 Health Care Conference on May 12, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Both presentations will be webcast live, with archive recordings available for 30 days on the company's Investor Center website. Tandem Diabetes Care is a leading insulin delivery and diabetes technology company based in San Diego, California.

https://ca.finance.yahoo.com/news/tandem-diabetes-care-announces-upcoming-200500355.html

Trending Today

Xerox Corporation ($XRX) Stock Forecast: Up 19.9% Today

First Solar Inc. ($FSLR) Stock Forecast: Up 6.7% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.2% Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Up 5.1% Today

C3.ai Inc. ($AI) Stock Forecast: Up 5.4% Today

GameStop Corp. ($GME) Stock Forecast: Up 5.1% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Up 21.8% Today

Cboe Global Markets Inc. ($CBOE) Stock Forecast: Up 7.4% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 7.2% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 5.1% Today

Tandem Diabetes Care, Inc. Price History

01.04.2026 - TNDM Stock was up 7.7%

• Tandem Diabetes Care (TNDM) experienced a strong bullish movement recently.
• Vanguard Capital Management's significant passive institutional investment of over 3.5 million shares in TNDM may have instilled confidence in other investors, contributing to the bullish trend.
• The raised price target by TD Cowen and the positive outlook on TNDM's new products driving future revenue growth likely attracted more investors to the stock.
• The announcement of upcoming conference presentations by Tandem Diabetes Care could have also generated excitement and optimism among investors, further fueling the bullish momentum.

21.03.2026 - TNDM Stock was down 5.2%

• Tandem Diabetes Care (TNDM) stock saw a decrease, despite TD Cowen boosting its price target to $28 and maintaining a Buy rating. The decline could be linked to investors taking profits after a period of price appreciation.
• The Chief Operating Officer of the company exercised restricted stock units (RSUs), with some shares held back for taxes. This action may have added selling pressure on the stock as more shares became available in the market.
• Although there was excitement surrounding the upcoming launch of the Mobi Tubeless product and a new pay-as-you-go program, these factors might not have been enough to counterbalance the short-term selling pressures that led to the observed decrease in stock value.

30.03.2026 - TNDM Stock was up 6.0%

• Tandem Diabetes Care disclosed upcoming conference appearances at two notable investor conferences, hinting at positive prospects and potentially exciting updates for investors.
• The FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes may have increased investor confidence in the company's innovative products and market potential.
• Vanguard Portfolio Management's substantial investment in Tandem Diabetes Care underscores investor interest and confidence in the company's future growth prospects.
• The overview of Tandem's market opportunity, dedication to innovation, and emphasis on commercial transformation likely contributed to the market's bullish trend as investors recognize the company's strong position in the global diabetes market.

30.03.2026 - TNDM Stock was up 7.6%

• Tandem Diabetes Care's stock experienced a strong bullish movement today.
• The bullish trend could be attributed to positive market sentiment driven by an increased price target for TNDM, highlighting the company's new pay-as-you-go program and Mobi Tubeless product as drivers for future revenue growth.
• Additionally, the FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes could have further boosted investor confidence in the company's innovative products and market potential.
• Significant stake in Tandem Diabetes Care Inc. by Vanguard Portfolio Management could also indicate institutional investor confidence in the company's long-term growth prospects.

28.03.2026 - TNDM Stock was down 6.6%

• The decrease in Tandem Diabetes Care's stock today may be due to profit-taking by investors following a period of positive momentum.
• Despite the favorable FDA clearance for the utilization of Control-IQ+ technology in pregnancy, the market's reaction might have been adverse as a result of already high expectations priced into the stock.
• The upgraded rating by Truist Securities and enthusiasm regarding the new pharmacy distributor model could have already been considered in the stock price, leading to a sell-off after the news.
• Investor concerns about the company's capacity to maintain growth and market presence in the competitive diabetes management sector may be contributing to a bearish outlook in the market.

28.03.2026 - TNDM Stock was down 5.5%

• The FDA clearance for Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy complicated by type 1 diabetes, while positive news, might have raised concerns about potential competition in the market leading to a bearish sentiment.
• Despite positive analyst upgrades from Truist Securities and Piper Sandler on Tandem's new pharmacy distributor model and strategy, the market may have reacted negatively due to profit-taking by investors after recent gains.
• Tandem Diabetes Care's strategic transformation initiatives outlined at the TD Cowen 46th Annual Health Care Conference could be seen as promising for the company's future growth, but the market may have interpreted them as long-term investments impacting short-term profitability, contributing to the bearish movement.
• Overall, the bearish movement in TNDM stock today could be a result of a combination of profit-taking, market competition concerns, and short-term impact of strategic transformations on profitability.

14.03.2026 - TNDM Stock was up 6.0%

• The surge in TNDM stock price could be attributed to the company being perceived as undervalued, with a GF Score of 74 indicating above-average potential for long-term returns.
• Maintaining a "Hold" rating and a target price of $22 might have provided investors with confidence in the current valuation of the stock.
• Positive sentiment from an AI analysis suggesting specific trading strategies and key support levels could have attracted more investors to TNDM.
• The overall bullish trend in the diabetes care market, with projected growth and technological advancements, might have positively impacted TNDM's stock price as it positions itself as a key player in the industry.

08.03.2026 - TNDM Stock was up 5.6%

• The bullish movement in Tandem Diabetes Care's stock today could be attributed to the company's request for shareholder approval for an increase in shares to its Long-Term Incentive Plan, signaling confidence in its future growth prospects.
• The projected growth in the Smart Insulin Management Devices Market, where Tandem Diabetes Care is a key player, could have also positively impacted investor sentiment and contributed to the stock's rise.
• Despite a reduction in stake by a notable financial institution, the overall market seems optimistic about Tandem Diabetes Care's performance, especially with the upcoming announcement of its first-quarter 2026 financial results, which investors are eagerly anticipating for insights into the company's trajectory.

13.03.2026 - TNDM Stock was up 5.5%

• TNDM stock started positively with a 5.69% gain, surpassing the S&P 500 performance.
• The optimistic outlook is supported by AI models suggesting favorable short-term sentiment and specific trading recommendations for large investors.
• In spite of a reduced price target by Goldman Sachs, TNDM stock remained strong, demonstrating robust confidence from investors in the company's potential for growth.
• Anticipated market expansion in diabetes care market by 2030, along with TNDM's innovative product range, likely influenced the market positively as investors foresee rising demand for diabetes care solutions.

07.03.2026 - TNDM Stock was up 6.2%

• Significant divestment of Tandem Diabetes Care shares by JPMorgan Chase & Co. initially raised investor concerns, but the market sentiment later turned positive.
• Despite Tandem Diabetes Care's ongoing lack of profitability, the stock witnessed a bullish trend leading up to the upcoming Q1 2026 financial results announcement.
• A mix of analyst opinions, resulting in a "Hold" consensus rating, and upgrades from some firms, likely influenced the positive investor sentiment as the company's potential was reassessed.
• Market enthusiasm and confidence in Tandem Diabetes Care's future performance, bolstered by beating earnings estimates for the quarter, drove the stock to a significant bullish movement.

07.03.2026 - TNDM Stock was down 5.8%

• The Smart Insulin Management Devices Market is projected to grow substantially by 2033, indicating a positive industry outlook. However, Tandem Diabetes Care's stock experienced a bearish trend.
• A reduction of 36.1% in Tandem Diabetes Care's stake by JPMorgan Chase & Co. could have contributed to the negative sentiment surrounding the stock.
• Despite beating earnings estimates, Tandem Diabetes Care remains unprofitable, leading to mixed analyst sentiment and a "Hold" consensus rating.
• The upcoming announcement of Tandem Diabetes Care's Q1 2026 results may have investors cautious, waiting for insights into the company's performance and future prospects before making investment decisions.

16.03.2026 - TNDM Stock was down 6.1%

• TNDM shares rose by 4.8% to $20.10, despite being undervalued, potentially prompting profit-taking by investors and contributing to the bearish trend.
• Mizuho Securities has maintained a "Hold" rating with a target price of $22, suggesting a neutral outlook that may not be driving significant positive momentum for the stock.
• Institutional trading strategies utilizing AI models could have resulted in selling pressure if recommended short positions were achieved.
• Anticipated growth in the diabetes care market until 2030 may have redirected investor attention towards other industry leaders, negatively impacting TNDM's stock performance in the short term.